Expert Interview
Discussing the recent label expansion Evkeeza (Evinacumab) by Regeneron to include children ages 5 to 11 years with rare homozygous familial hypercholesterolemia (HoFH)
Ticker(s): REGNInstitution: NYU
Clinical Assistant Professor of Medicine at NYU, Lipidology & Cardiovascular Disease Prevention & Diplomate American Board of Clinical Lipidology
Currently treats 6 patients with HoFH and has prescribed Evkeeza to 3 patients.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
